Nanomol Technologies is also active in several European and National Collaborative projects. Specifically, NANOMOL Technologies has been involved in several consortia to carry out the following R+D projects dealing with the application of Micro and Nanotechnology to biomedical and health care purposes.

Nanomol technologies



Micro4Nano (Multifunctional nanocarriers for nonlinear microscopy: new tools for biology and medicine) is an International Consortium funded by the European Union in the framework of H2020-MSCA-RISE-2020, Research and Innovation Staff Exchange (Grant Agreement #101007804). 

The direct 3D visualization of biological tissues, made possible by multiphoton microscopy, has the potential to revolutionize our understanding of the relation between the structure and function of biological tissues, opening the way to impressive applications in biomedicine and drug delivery, and even in phytotherapy, and agricultural and food industries. Micro4Nano develop new approaches and methods towards the 3D visualization of biological tissues, combining imaging of fluorescent species, with structural, functional, and chemical information. 

A new generation of multifunctional nanocarriers for two-photon microscopy and drug delivery, which include our DELOS nanovesicles, are designed in this project and extensively exploited towards real-time monitoring of living cells and tissues. 

Micro4Nano promotes training and international multidisciplinary collaborations between experts in complementary fields, including microscopy, drug delivery, spectroscopy, chemical synthesis, theoretical and computational chemistry.



The NABIHEAL project "Antimicrobial Nanostructured Biomaterials for Complex Wound Healing", is a project coordinated by the Center for Biomedical Research Network (CIBER) at the Institute of Materials Science of Barcelona (ICMAB, CSIC). It is funded by the Horizon Europe Research and Innovation program with a total budget of almost 5 million euros. It started on January 11, 2023 and Nanomol Technologies will collaborate in it for 4 years.  

NABIHEAL aims to address two medical needs still unmet today in complex wound healing: on the one hand, affordable treatments for wound infections and prevention of complications during healing; and on the other hand, a strategy to optimize the composition and efficacy of wound healing drugs and dressings.  

The project aims to obtain innovative multifunctional biomaterials for wound healing using affordable EU-based manufacturing technologies. In the long term, NABIHEAL could become a revolutionary alternative to silver in wound healing dressings.  

In this project Nanomol Technologies has a leading role in the biomaterial scale-up tasks of the project, in which our DELOS nanoformulation platform is used in order to develop these functional biomaterials. We co-lead as well the Business Development and Exploitation work package together with the Basque company Histocell SL



PHOENIX is an European initiative consisting of a Pharmaceutical Open Innovation Test Bed (OITB) for Enabling Nano-pharmaceutical Innovative Products. This initiative is run by a consortium composed of experienced and well-established beneficiaries in their respective fields, which provide PHOENIX-OITB all necessary infrastructures to cover all the aspects of GMP manufacturing of nano-pharmaceuticals from development and technology transfer through scale up to regulatory guidance. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 953110. 

PHOENIX aims to enable the seamless, timely and cost-friendly transfer of nano-pharmaceuticals from lab bench to clinical trials by providing the necessary advanced, affordable and easily accessible PHOENIX-OITB. PHOENIX-OITB started last March 2021 and offer a consolidated network of facilities, technologies, services and expertise for all the technology transfer aspects from characterisation, testing, verification up to scale up, GMP compliant manufacturing and regulatory guidance.  

PHOENIX-OITB develop and establish new facilities and upgrade existing ones to make them available to SMEs, start-ups and research laboratories for scale-up, GMP production and testing of nano-pharmaceuticals. 

In this project, Nanomol Technologies lead the Quality Management activities, and provide two nanopharmaceutical demo-cases based on our proprietary DELOS nanoformulation technology. Regarding the two demo cases, we are focused on the scale-up and implementation of cGMP production equipment for the DELOS technology and cGMP analytical development for DELOS-based nanomedicines, using our brand new HPLC ACQUITY Arc System equipment from Waters Corporation. 



TECNIOspring PLUS project is ACCIÓ's international talent programme co-financed by the H2020 Marie Skłodowska-Curie actions of the European Union. The aim of the programme is to boosts technology transfer processes by offering R&D companies and centres 2-year employment contracts to host an experienced researcher. The project was granted in May 2019 in order for Nanomol Technologies S.L to contract PhD. Ivana Malvacio as qualified researcher.

The main goal of the project is to develop the potential of the patented DELOS technology platform to produce high quality cosmetic ingredients, based on lipid nanovesicle systems for the delivery of biotechnological actives.

By combining experimental approach with computational simulations, new DELOS nanovesicles for cosmetic applications will be prototyped. The developed systems will be designed to integrate different cosmetic ingredients and active biomolecules for skin and hair applications. The biocompatibility, penetration to the skin and efficacy of the developed active-conjugated DELOS nanovesicles will be tested in-vitro and ex-vivo.



Smart-4-Fabry (S4F) is the acronym of a H2020 funded Project that stands for “Smart functional GLA-nanoformulation for Fabry disease”. Smart-4-Fabry is a collaborative Project funded under the H2020 EU Research and Innovation programme, and started on the 1st January 2017 and will last four years. The S4F Project has been conceived to obtain a new nanoformulation of GLA, that will improve the efficacy and tolerability of this new drug in comparison to the actual treatment for Fabry Disease with non-formulated GLA. In the case of the Fabry Disease (FD), the deficiency of α-Galactosidase A (GLA) enzyme results in the cellular accumulation of neutral glycosphingolipids, leading to widespread vasculopathy with particular detriment to the kidneys, heart and central nervous system. The final benefit expected with S4F project will be seen as considerable reduction on the Fabry disease treatment costs and a substantial improvement in the efficacy of GLA enzyme, together with life-quality of Fabry disease patients. In this Project, Nanomol Technologies is involved in pharmaceutical development of the new reformulated GLA based drug, scale-up of the technology which permits to produce the new nanoformulation, and GMP implementation of a pilot productive line to obtain the new nanoformulation for future clinical testing.



Nanonafres project consist of a multidisciplinary consortium of seven Catalan partners, including public scientific research centres, small companies, primary care centres and public hospitals with the aim to develop a novel pharmaceutical formulation that integrates a marketed free recombinant human Epidermal Growth Factor (rh-EGF) in nanovesicles (NV-rh-EGF) to enable its topical administration and promote wound healing of venous leg ulcers. The Project was granted in October 2016 with a financial programme (RIS3CAT) by the Generalitat of Catalonia (FEDER funds), which is aligned with the European Commission (EC) National/Regional Research and Innovation Strategies for Smart Specialisation (RIS3 strategies). This project is part of the TECSALUT RIS3CAT community coordinated by LEITAT Technology Centre. Nanonafres project is expecting to last for 42 months and will carry out pharmaceutical development of the new nanoformulation required to perform nonclinical testing as well as a clinical study in patients with venous leg ulcers to establish the safety of NV-rh-EGF and obtain an efficacy preliminary proof of concept.  Within this framework, Nanomol Technologies is the Leader and Technological Partner of the Nanonafres Project.



The idea of TheraGlio FP7 Cooperation project is to develop a multimodal imaging system for Theranostics (therapy+diagnosis) of patients bearing malignant glioma, the most common primary brain tumour. This technology will avail of new generation Microbubbles (MBs), in which development NANOMOL Technologies is involved, that can simultaneously act as drug delivery system and contrast agent for Magnetic Resonance Imaging, intra-operative Contrast-Enhanced Ultrasound and intra-operative fluorescence microscopic.



The project Nano-Oligomed, started in December 2017, is funded by RISE Marie Curie actions from H2020 and is entitled “Hybrid Nanostructured Oligonucleotide Platforms for Biomedical Applications”. The scientific aim of Nano-OligoMed is the creation of degradable hybrid structures that combine the rigid, inert silica and soft nanovesicle-carriers with the delicate programmable oligonucleotides or artificial oligonucleotide-mimics. The possibility to develop novel oligonucleotide-based materials will enable a) the degradation of the drug carrier at the presence of a specific input as a function of the intrinsic bio-responsive feature of oligonucleotides, b) the activation of a therapeutic function as a result of the bio-molecular interaction between the oligonucleotide-based material and the molecular target (i.e. miRNAs) and c) the delivery of the chemical payload upon cell internalization. With these objectives and in the framework of a public-private consortium, international academic networking, broadening of the research skills and educational activities are supplied to young (PhD students) and senior scientists to enable them acquire specific competences in the field of materials sciences, nanotechnology, molecular biology and molecular medicine.



The main target of this ITN network is the education of a new generation of scientists for the development, via breakthrough research, of two technologically relevant applications, namely two-photon microscopy (2PM) and two-photon polymerization (2PP), with enormous applicative potential in bioimaging, biomedicine, and rapid prototyping techniques. In this ITN, NANOMOL Technologies is involved in the scaling-up of Organic Nanoparticles (ONP) production processes to be used in photonic applications.